Colon Cancer Clinical Trial

An Open Label Study of a Peptide Vaccine in Patients With Stage III Colon Cancer

Summary

EP2101 is a new cancer vaccine containing 10 different peptide antigens. The vaccine is designed to activate the immune system to develop a response against tumor cells in order to delay or prevent the recurrence of cancer. This study will test the safety and measure the level of immune stimulating capability of EP2101 in patients with Colon Cancer.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Confirmed diagnosis of Colon Cancer, stage III
At least four weeks following prior standard treatment, with no evidence of disease
Must use adequate birth control

Exclusion Criteria:

Prior cancer vaccine therapy or concurrent participation in any other investigational study
A history of HIV, Hepatitis B or C, or any other acute medical condition which may compromise patient safety or the activity of the study vaccine treatment
A history of adverse reactions following administration of any vaccines, or a history of hypersensitivity to any components of the study vaccine
Women who are pregnant, intend to become pregnant, or who are breast feeding

Study is for people with:

Colon Cancer

Phase:

Phase 1

Estimated Enrollment:

18

Study ID:

NCT00054912

Recruitment Status:

Completed

Sponsor:

Epimmune

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 9 Locations for this study

See Locations Near You

University of Southern California School of Medicine
Los Angeles California, 90033, United States
University of California, San Diego
San Diego California, 92037, United States
Cancer Centers of Florida
Orlando Florida, 32806, United States
New York Oncology Hematology
Albany New York, 12208, United States
Duke University Medical Center
Durham North Carolina, 27710, United States
Mary Crowley Medical Research Center
Dallas Texas, 75246, United States
Tyler Cancer Center
Tyler Texas, 75702, United States
University of Washington
Seattle Washington, 91895, United States
Cancer Care Northwest
Spokane Washington, 99218, United States

How clear is this clinincal trial information?

Study is for people with:

Colon Cancer

Phase:

Phase 1

Estimated Enrollment:

18

Study ID:

NCT00054912

Recruitment Status:

Completed

Sponsor:


Epimmune

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider